Skip to content

Home
Disease & Drugs
Health Tidings
Wellness
Policy & Acquisitions
- Mergers & Acquisitions
- Regulatory & Health Policy
About Us
Contact Us

Search for:

Home
Disease & Drugs
Health Tidings
Wellness
Policy & Acquisitions
- Mergers & Acquisitions
- Regulatory & Health Policy
About Us
Contact Us

September 2026

AskBio GenePHIT trial evaluates umiposgene parvec gene therapy in non-ischemic HFrEF

AskBio Completes GenePHIT Enrollment with Well-Characterized Non-Ischemic H...

AskBio Completes GenePHIT Enrollment with Well-Characterized Non-Ischemic H... Read Post »

Search

Recent Posts

AskBio Completes GenePHIT Enrollment with Well-Characterized Non-Ischemic HFrEF Cohort
Zanidatamab Plus Chemotherapy Improves Survival in HER2+ GEA
Taltz and Zepbound Sustain One-Year Benefits in Psoriatic Disease with Obesity
First New ET Treatment in Nearly 30 Years: BESREMi Wins FDA Approval
Lilly to Acquire Merida Biosciences for Up to $2.875 Billion to Advance Precision Autoantibody Therapies

Recent Comments

No comments to show.

Archives

September 2026
August 2026
July 2026
June 2026
May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025

About Us

About Us
Internship with us
Terms and Conditions

Categories

Clinical Trials
CRO
Disease & Drugs
Drugs Safety Alert
Food
Generics
Health Tidings
Lifestyle
Manufacturing
Medical Devices
Mergers & Acquisitions
New Drug Approval
Policy & Acquisitions
Regulatory & Health Policy
Research
Wellness
Women & Child Health

Search

Recent Posts

AskBio Completes GenePHIT Enrollment with Well-Characterized Non-Ischemic HFrEF Cohort
Zanidatamab Plus Chemotherapy Improves Survival in HER2+ GEA
Taltz and Zepbound Sustain One-Year Benefits in Psoriatic Disease with Obesity
First New ET Treatment in Nearly 30 Years: BESREMi Wins FDA Approval
Lilly to Acquire Merida Biosciences for Up to $2.875 Billion to Advance Precision Autoantibody Therapies

Categories

Clinical Trials (814)
CRO (3)
Disease & Drugs (61)
Drugs Safety Alert (71)
Food (35)
Generics (52)
Health Tidings (864)
Lifestyle (28)
Manufacturing (11)
Medical Devices (7)
Mergers & Acquisitions (168)
New Drug Approval (380)
Policy & Acquisitions (60)
Regulatory & Health Policy (19)
Research (138)
Wellness (56)
Women & Child Health (10)

Follow Us:

Instagram Facebook Linkedin-in X-twitter Whatsapp

Quick Links

Home
Blog
Contact Us

Company

About Us
Our Founder
Our Team
Advisory Panel
Newsletter
Whitepaper

Important Link

Advertise With Us
Internship With Us
Sources of Information
Editorial Process Disclosure

Pharmacally a brand of
MedCognize Communications (OPC) Pvt. Ltd.

Address

Gat No. 405, Plot No.17, Nighoje, Chakan Industrial Area, Pune-410501

Email Address

contactus@pharmacally.com

Contact Number

Disclaimer: The content provided on the website is for information purposes only and is not intended as medical advice, diagnosis or treatment. Always seek doctors and other health provider’s advice in person regarding your any medical query or condition.

Privacy Policy
Terms & Condition

Copyright © 2026 Pharmacally | Developed by WebDroid Technologies

Newsletter

Subscribe for evidence-based updates and medical insights, delivered directly to your mailbox.

Please enable JavaScript in your browser to complete this form.

Email

Email *

Scroll to Top